COVID-19 and hydroxychloroquine: Is the wonder drug failing?
作者信息
Paliani Ugo, Cardona Andrea
机构信息
Division of Internal Medicine and Sport Cardiology. Media Valle del Tevere Hospital, Todi, Umbria, Italy; Umbria Covid Hospital, Todi, Umbria, Italy.
Division of Internal Medicine and Sport Cardiology. Media Valle del Tevere Hospital, Todi, Umbria, Italy; Umbria Covid Hospital, Todi, Umbria, Italy; Division of Cardiovascular Medicine - Department of Internal Medicine. The Ohio State University, Columbus, Ohio, USA.
出版信息
Eur J Intern Med. 2020 Aug;78:1-3. doi: 10.1016/j.ejim.2020.06.002. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
COVID-19 and hydroxychloroquine: Is the wonder drug failing?
Eur J Intern Med. 2020 Aug;78:1-3. doi: 10.1016/j.ejim.2020.06.002. Epub 2020 Jun 4.
2
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?].
J Fr Ophtalmol. 2020 Jun;43(6):548-549. doi: 10.1016/j.jfo.2020.04.014. Epub 2020 Apr 30.
3
Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Emerg Microbes Infect. 2020 Dec;9(1):830-832. doi: 10.1080/22221751.2020.1760145.
4
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
5
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Heart Rhythm. 2020 Jul;17(7):e231-e232. doi: 10.1016/j.hrthm.2020.04.016. Epub 2020 Apr 14.
6
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
Dermatol Ther. 2020 Jul;33(4):e13499. doi: 10.1111/dth.13499. Epub 2020 May 22.
7
[Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].
Orv Hetil. 2020 Apr 1;161(17):689-691. doi: 10.1556/650.2020.31817.
8
BET 2: Hydroxychloroquine in the treatment of COVID-19.
Emerg Med J. 2020 Jul;37(7):451-453. doi: 10.1136/emermed-2020-210221.3.
9
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
10
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
Eur J Clin Invest. 2020 Nov;50(11):e13407. doi: 10.1111/eci.13407. Epub 2020 Sep 25.
引用本文的文献
1
Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19.
Infect Dis Clin Microbiol. 2023 Jun 23;5(2):94-105. doi: 10.36519/idcm.2023.206. eCollection 2023 Jun.
2
Computational studies reveal Fluorine based quinolines to be potent inhibitors for proteins involved in SARS-CoV-2 assembly.
J Fluor Chem. 2021 Oct;250:109865. doi: 10.1016/j.jfluchem.2021.109865. Epub 2021 Aug 11.
3
Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication.
Cell Discov. 2021 May 24;7(1):37. doi: 10.1038/s41421-021-00279-w.
4
Embracing the Uncertainty: an Important Lesson from COVID-19.
J Gen Intern Med. 2021 Nov;36(11):3562-3564. doi: 10.1007/s11606-021-06809-2. Epub 2021 Apr 26.
5
Familiar Dermatologic Drugs as Therapies for COVID-19.
Actas Dermosifiliogr (Engl Ed). 2021 Feb;112(2):118-126. doi: 10.1016/j.ad.2020.09.004. Epub 2020 Oct 10.
6
COVID-19 associated complications and potential therapeutic targets.
Eur J Pharmacol. 2020 Nov 5;886:173548. doi: 10.1016/j.ejphar.2020.173548. Epub 2020 Sep 12.
7
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Rheumatol Int. 2020 Nov;40(11):1741-1751. doi: 10.1007/s00296-020-04694-2. Epub 2020 Sep 2.
8
COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
Eur J Intern Med. 2020 Oct;80:121. doi: 10.1016/j.ejim.2020.07.017. Epub 2020 Jul 21.
9
Sex-related differences in COVID-19 lethality.
Br J Pharmacol. 2020 Oct;177(19):4375-4385. doi: 10.1111/bph.15207. Epub 2020 Aug 5.
10
Chloroquine and COVID-19: A western medical and scientific drift?
Eur J Intern Med. 2020 Aug;78:4-5. doi: 10.1016/j.ejim.2020.06.020. Epub 2020 Jun 23.
本文引用的文献
1
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
2
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
3
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
BMJ. 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844.
4
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
5
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
6
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024. Epub 2020 Apr 7.
7
Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
J Rheumatol. 2020 Jun 1;47(6):787-790. doi: 10.3899/jrheum.200395. Epub 2020 Apr 8.
8
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Int J Antimicrob Agents. 2020 May;55(5):105960. doi: 10.1016/j.ijantimicag.2020.105960. Epub 2020 Apr 3.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.
Zotero 插件